All In Biotech

Drug Trial Radar · NCT07681713

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

Evaluation of Long-Term Efficacy of Vatiquinone for the Treatment of Friedreich's Ataxia

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 15, 2026

Primary completion

Mar 15, 2029

Study completion Mar 15, 2029

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 7 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.

Conditions

  • Friedreich's Ataxia

Interventions

  • VatiquinoneDrug

    Vatiquinone will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Modified Friedreich's Ataxia Rating Scale (mFARS) Score at Month 24Time frame: Baseline, Month 24

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • University of South Florida

    Tampa, Florida

  • University of Iowa

    Iowa City, Iowa

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Hôpital Érasme (Hôpital Universitaire de Bruxelles)

    Brussels, Belgium

  • University of Campinas

    Campinas, São Paulo, Brazil

  • Centre Hospitalier de l'Universite de Montreal CHUM

    Montreal, Quebec, Canada

  • Institut du Cerveau et de la Moelle Epinière

    Paris, France

  • Hospital Sant Joan de Deu

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.